Laurie Marzullo1. 1. Division of Pediatric Emergency Medicine, University of Alabama at Birmingham, Birmingham, Alabama 35233, USA. lmarzullo@peds.uab.edu
Abstract
PURPOSE OF REVIEW: Acetaminophen poisoning accounts for a disproportionate percentage of all toxic ingestions, and can be life-threatening. This article reviews the mechanism and presentation of acetaminophen toxicity, as well as its treatment, including current thinking and treatment recommendations. RECENT FINDINGS: N-acetylcysteine acts to detoxify acetaminophen in several ways, but primarily by increasing the synthesis and availability of glutathione, which binds and inactivates the highly reactive and hepatotoxic acetaminophen metabolite N-acetyl-p-benzoquinoneimine. The US Food and Drug Administration has approved an intravenous formulation of N-acetylcysteine, thus allowing the treatment time to be decreased from the 72 hr most commonly used for the oral regimen, to only 20 hr. This comes after many years of accepted intravenous N-acetylcysteine use in Europe and Canada, and much controversy as to the superiority of both treatments. This review summarizes this controversy, and offers a framework to develop a safe treatment plan that has the optimal outcome for the patient, as well as reflecting knowledge of the potential caveats at work. It describes side effects of N-acetylcysteine treatment, as well as relative indications to choose one route of treatment over the other. SUMMARY: Acetaminophen can lead to irreversible liver damage and even death in acute overdose. Outcome is related to the swiftness in which the antidote (N-acetylcysteine) is provided. In the United States, there are now available both the oral and intravenous forms of N-acetylcysteine, and pros and cons exist for each. With brisk and adequate treatment using either route, recovery can be complete, and liver function can be restored.
PURPOSE OF REVIEW: Acetaminophenpoisoning accounts for a disproportionate percentage of all toxic ingestions, and can be life-threatening. This article reviews the mechanism and presentation of acetaminophentoxicity, as well as its treatment, including current thinking and treatment recommendations. RECENT FINDINGS:N-acetylcysteine acts to detoxify acetaminophen in several ways, but primarily by increasing the synthesis and availability of glutathione, which binds and inactivates the highly reactive and hepatotoxicacetaminophen metabolite N-acetyl-p-benzoquinoneimine. The US Food and Drug Administration has approved an intravenous formulation of N-acetylcysteine, thus allowing the treatment time to be decreased from the 72 hr most commonly used for the oral regimen, to only 20 hr. This comes after many years of accepted intravenous N-acetylcysteine use in Europe and Canada, and much controversy as to the superiority of both treatments. This review summarizes this controversy, and offers a framework to develop a safe treatment plan that has the optimal outcome for the patient, as well as reflecting knowledge of the potential caveats at work. It describes side effects of N-acetylcysteine treatment, as well as relative indications to choose one route of treatment over the other. SUMMARY:Acetaminophen can lead to irreversible liver damage and even death in acute overdose. Outcome is related to the swiftness in which the antidote (N-acetylcysteine) is provided. In the United States, there are now available both the oral and intravenous forms of N-acetylcysteine, and pros and cons exist for each. With brisk and adequate treatment using either route, recovery can be complete, and liver function can be restored.
Authors: Rupesh Raina; Manpreet K Grewal; Martha Blackford; Jordan M Symons; Michael J G Somers; Christoph Licht; Rajit K Basu; Sidharth Kumar Sethi; Deepa Chand; Gaurav Kapur; Mignon McCulloch; Arvind Bagga; Vinod Krishnappa; Hui-Kim Yap; Marcelo de Sousa Tavares; Timothy E Bunchman; Michelle Bestic; Bradley A Warady; Maria Díaz-González de Ferris Journal: Pediatr Nephrol Date: 2019-08-24 Impact factor: 3.714
Authors: Mashiko Setshedi; Lisa Longato; Dennis R Petersen; Martin Ronis; William C Chen; Jack R Wands; Suzanne M de la Monte Journal: Alcohol Clin Exp Res Date: 2011-07-25 Impact factor: 3.455
Authors: Michael R Narkewicz; Simon Horslen; Regina M Hardison; Benjamin L Shneider; Norberto Rodriguez-Baez; Estella M Alonso; Vicky L Ng; Mike A Leonis; Kathleen M Loomes; David A Rudnick; Philip Rosenthal; Rene Romero; Girish C Subbarao; Ruosha Li; Steven H Belle; Robert H Squires Journal: Clin Gastroenterol Hepatol Date: 2018-04-30 Impact factor: 11.382
Authors: Robert H Squires; Anil Dhawan; Estella Alonso; Michael R Narkewicz; Benjamin L Shneider; Norberto Rodriguez-Baez; Dominic Dell Olio; Saul Karpen; John Bucuvalas; Steven Lobritto; Elizabeth Rand; Philip Rosenthal; Simon Horslen; Vicky Ng; Girish Subbarao; Nanda Kerkar; David Rudnick; M James Lopez; Kathleen Schwarz; Rene Romero; Scott Elisofon; Edward Doo; Patricia R Robuck; Sharon Lawlor; Steven H Belle Journal: Hepatology Date: 2013-02-04 Impact factor: 17.425
Authors: Erin A McClure; Susan C Sonne; Theresa Winhusen; Kathleen M Carroll; Udi E Ghitza; Aimee L McRae-Clark; Abigail G Matthews; Gaurav Sharma; Paul Van Veldhuisen; Ryan G Vandrey; Frances R Levin; Roger D Weiss; Robert Lindblad; Colleen Allen; Larissa J Mooney; Louise Haynes; Gregory S Brigham; Steve Sparenborg; Albert L Hasson; Kevin M Gray Journal: Contemp Clin Trials Date: 2014-08-30 Impact factor: 2.226